RE:RE:RE:RE:RE:RE:Hiring SternAntibe trades at .40 today. That's what Dan Legault thinks its worth. Baked into that price is the entirety of phase 2 data including acetaminophen 'significance'.
I posted about Stern to clarify what it could do for Antibe which includes what has to this time been missing: a proper response to phase 2 with reference to acetaminophen 'significance'. I've included that post below.
Hiring Stern
...was the best thing management has done to advance Antibe.
Unlike many here i remain a realist about Antibe's immediate future. I believe Antibe will receive partnership offers and will turn them down because the offers will not price in the potential and upside in 346.
Antibe will be 'lowballed'. The reason why is because of the acetaminophin 'significance' that crushed Antibe's share price when otherwise brilliant phase 2 data was released.
Potential partners will not pay a premium for potential until that 'significance' is erased by further data. This means phase 3 results that address the acetaminophin 'significance'.
Presently the company is pretending all is well.
Stern will--If they are the top pros they were hired to be, and are being paid to be, around five months into their six month contract--sit Dan down and explain to him the facts of life.
Antibe must come clean, preferably in the highest profile industry journal possible, about the acetaminophen significance. The article should explain that the initial phase 3 tests of 346 will have more patients, more doses over longer periods and all will include post test acetaminophin results that will be clinically 'insignificant'.
That's what top public relations people do for their clients.
Then, Antibe can resume it's inevitable rise premised on the superior science behind 346. Presently, that science is under a cloud creating the present situation which must be addressed.